| Outcome | Probability | Yes Bid | Yes Ask | 24h Change | Volume | |
|---|---|---|---|---|---|---|
| Before April 4 | 0% | 0¢ | 0¢ | — | $0 | Trade → |
| Before April 6 | 0% | 0¢ | 0¢ | — | $0 | Trade → |
| Before April 8 | 0% | 0¢ | 0¢ | — | $0 | Trade → |
| Before April 10 | 0% | 0¢ | 0¢ | — | $0 | Trade → |
| Before April 11 | 0% | 0¢ | 0¢ | — | $0 | Trade → |
This market asks when the U.S. Food and Drug Administration (FDA) will grant approval for orforglipron, an investigational metabolic therapy. The timing matters to patients, clinicians, investors, and competitors because approval determines when the drug can be marketed and reimbursed in the U.S.
Orforglipron is an investigational small-molecule therapy that targets GLP-1 receptor pathways and has been developed for metabolic indications such as obesity and type 2 diabetes; it advanced through clinical trials and regulatory review processes typical for new therapies. FDA approval requires a complete submission from the sponsor and review of clinical efficacy, safety, and manufacturing controls; approval timing reflects both trial results and regulatory steps rather than commercial plans. The broader GLP-1 class and recent approvals for related therapies create a competitive and regulatory context that influences scrutiny of efficacy and safety.
Market odds on this event reflect the aggregated expectations of traders about when approval will occur based on public information and perceived risks; they are a snapshot of collective judgment, not a deterministic prediction. Use odds to monitor how new data or regulatory actions shift expectations, but do not treat them as guarantees of any specific date.
Each outcome maps to a mutually exclusive timing window or result for FDA approval (for example: approval by a specified period, approval in a later period, or not approved by a cutoff). The market resolves to the outcome that matches the official FDA decision date or resolution criteria defined by the event.
If the sponsor files a complete NDA/BLA and the FDA accepts it for review, the agency typically sets a target action date (PDUFA date) based on the review standard; priority review shortens and standard review lengthens that target. The PDUFA date is a key milestone that directly anchors which timing outcome will resolve in this market.
Major drivers include public announcements of NDA/BLA submission or acceptance, scheduling of an advisory committee meeting, issuance of a PDUFA date, FDA requests for more data or inspections, and the release of any safety findings or labeling negotiations.
Yes. Manufacturing deficiencies or failed facility inspections can trigger corrective actions, delay approval, or lead to requests for additional documentation; such issues often extend timelines independently of clinical efficacy results.
Monitor sponsor press releases and SEC filings for submission or regulatory updates, FDA public docket entries and press releases for submission acceptance, PDUFA dates, advisory committee announcements, and official FDA letters (e.g., complete response letters or approval letters) that specify decision dates.